The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Irbesartan BMS irbesartan | Bristol-Myers Squibb Pharma EEIG | Hypertension | 🇪🇺 EU 2007-01-19 | Order → |
| Irbesartan Hydrochlorothiazide BMS irbesartan;hydrochlorothiazide | Bristol-Myers Squibb Pharma EEIG | Hypertension | 🇪🇺 EU 2007-01-19 | Order → |
| Irbesartan Zentiva (previously Irbesartan Winthrop) irbesartan | Zentiva k.s. | Hypertension | 🇪🇺 EU 2007-01-19 | Order → |
| Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop) irbesartan;hydrochlorothiazide | sanofi-aventis groupe | Hypertension | 🇪🇺 EU 2007-01-18 | Order → |
| Imprida amlodipine;valsartan | Novartis Europharm Ltd | Hypertension | 🇪🇺 EU 2007-01-17 | Order → |
| Insulin Human Winthrop insulin human | sanofi-aventis Deutschland GmbH | Diabetes Mellitus | 🇪🇺 EU 2007-01-17 | Order → |
| Exforge amlodipine;valsartan | Novartis Europharm Limited | Hypertension | 🇪🇺 EU 2007-01-16 | Order → |
| Inovelon rufinamide | Eisai GmbH | Epilepsy | 🇪🇺 EU 2007-01-16 | Order → |
| Copalia amlodipine;valsartan | Novartis Europharm Limited | Hypertension | 🇪🇺 EU 2007-01-15 | Order → |
| Dafiro amlodipine;valsartan | Novartis Europharm Limited | Hypertension | 🇪🇺 EU 2007-01-15 | Order → |
| Elaprase idursulfase Exceptional circumstancesAdditional monitoring | Takeda Pharmaceuticals International AG Ireland Branch | Mucopolysaccharidosis II | 🇪🇺 EU 2007-01-08 | Order → |
| Tandemact pioglitazone;glimepiride | CHEPLAPHARM Arzneimittel GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2007-01-08 | Order → |
| Adrovance alendronic acid;colecalciferol | Organon N.V. | Osteoporosis, Postmenopausal | 🇪🇺 EU 2007-01-04 | Order → |
| Diacomit stiripentol | Biocodex | Myoclonic Epilepsy, Juvenile | 🇪🇺 EU 2007-01-03 | Order → |
| Byetta exenatide | AstraZeneca AB | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2006-11-20 | Order → |
| Sprycel dasatinib (anhydrous) | Bristol-Myers Squibb Pharma EEIG | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 🇪🇺 EU 2006-11-20 | Order → |
| Suboxone buprenorphine;naloxone | Indivior Europe Limited | Opioid-Related Disorders | 🇪🇺 EU 2006-09-26 | Order → |
| Champix varenicline | Pfizer Europe MA EEIG | Tobacco Use Cessation | 🇪🇺 EU 2006-09-25 | Order → |
| Gardasil human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) | Merck Sharp & Dohme B.V. | Papillomavirus Infections; Uterine Cervical Dysplasia; Condylomata Acuminata; Immunization | 🇪🇺 EU 2006-09-20 | Order → |
| Luminity perflutren | Lantheus EU Limited | Echocardiography | 🇪🇺 EU 2006-09-20 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.